Irfan A Asangani

Irfan A Asangani is an Associate Professor of Cancer Biology at the Perelman School of Medicine, University of Pennsylvania. He is affiliated with the Abramson Family Cancer Research Institute and the Penn Epigenetics Institute, focusing on molecular epigenetic events in cancer progression and therapy resistance.

• Education: B.S. and M.S. in Biochemistry (First Class) from Madras University, India; Ph.D. in Cancer Biology (Summa cum laude) from Klinikum Mannheim/DKFZ/Heidelberg University, Germany.

Research Interests include cancer epigenetics, chromatin regulation, non-coding RNA, androgen receptor signaling, and mechanisms of resistance to targeted therapies. His lab employs multidisciplinary approaches to translate epigenetic insights into clinical tools for diagnostics, prognostics, and combination therapies.

Recent Publications highlight roles of chromatin regulators like NSD2 in prostate cancer, LCMT1 loss in therapy resistance, and SOX4 in cellular reprogramming. Themes span epigenetic reprogramming, metabolic adaptations, and combinatorial strategies to suppress resistant tumor cells.

Lab Affiliation: The Asangani Lab at Penn investigates transcriptional addiction in cancer cells, collaborating with Abramson Cancer Center and the Penn Epigenetics Institute.